GLP-1 Boom Fuels New Stigma for Non-Users as #Ozempic Views Jump to 1.2 Billion
Updated
Updated · The Boston Globe · Aug 31
GLP-1 Boom Fuels New Stigma for Non-Users as #Ozempic Views Jump to 1.2 Billion
3 articles · Updated · The Boston Globe · Aug 31
Summary
Patients declining GLP-1 weight-loss drugs say they now face pressure from co-workers, relatives and doctors to justify not taking the shots, turning non-use itself into a source of shame.
1.2 billion TikTok views for #Ozempic in 2023, up from 2 million in 2021, helped push the drugs into mainstream culture, where their effects now reach restaurants, fashion and even marriage talk.
37-year-old women interviewed in the report cited cost, lifelong use and side-effect risks—from nausea to possible eye damage—as reasons to avoid the medications despite repeated prodding.
Weight-stigma experts and clinicians say the drugs have medicalized body scrutiny rather than reduced it, leaving people judged whether they take GLP-1s, lose weight naturally or accept their size.